Essential cookies by default. The browser ID, load-time metrics and error replays only run if you choose "Accept all".
AN-PEP (Prolyl Endopeptidase)
An oral enzyme from the mould Aspergillus niger that breaks down gluten in the stomach. Small trials show it lowers the gluten reaching the small intestine after a meal, but it is not a treatment for coeliac disease. It does not make gluten safe in coeliac disease or wheat allergy, and it must not replace a gluten-free diet.
What the evidence says
AN-PEP doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from medium-quality randomised trials published 2006–2025 with a typical study size of 18 participants.
Based on 11 studies · 4 RCTs · 114 total participants
Study base
11 studies indexedBy outcome
Every outcome below: Too few graded studies.
Emerging 3.5: two small placebo-controlled crossover trials (12 and 18 people) consistently show the enzyme degrades most gluten in the stomach, but that is a surrogate measure. The trials in coeliac disease missed their primary endpoints, the 40-person randomised trial found no difference from placebo in stool gluten peptides, and no trial shows a clinical benefit such as protected intestinal lining or fewer symptoms against placebo.
30 trials ongoing or recruiting · 73 completed on ClinicalTrials.gov
20 of the completed trials have posted results
Registered trials show research momentum for AN-PEP, not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Nov 2026
AN-PEP is a prolyl endopeptidase produced by the mould Aspergillus niger. Gluten is rich in the amino acid proline, which makes parts of it resistant to human digestive enzymes, and in coeliac disease those surviving fragments trigger the immune attack on the small intestine.
This enzyme cuts protein chains next to proline, works at stomach acidity and resists pepsin, so it can break gluten down in the stomach before it reaches the small intestine.
In two small crossover trials, one in 12 healthy volunteers and one in 18 people who reported gluten sensitivity, it sharply reduced the gluten measured in the stomach and duodenum after a gluten-containing meal.
The trials in coeliac disease did not show protection: a 16-person pilot could not show any effect on the intestine, and a 40-person randomised trial found no difference from placebo in gluten peptides in stool. A study of enzyme-treated bread found no symptom benefit in people with self-reported gluten sensitivity.
It is not a treatment for coeliac disease, it does not make gluten safe in coeliac disease or wheat allergy, and it must not replace a gluten-free diet. A strict gluten-free diet remains the only established treatment.
Its most defensible use is as an extra layer against accidental or trace gluten in people who already avoid gluten, and even that rests on gluten measurements in small, short studies rather than on clinical outcomes.
Cleaves protein chains next to proline, breaking down the proline-rich gluten fragments that human digestive enzymes leave intact, including the fragments coeliac T cells react to.
Works best at pH 4-5, stays stable at pH 2 and resists pepsin, so it can act in the stomach before gluten reaches the small intestine.
In laboratory models other food proteins and baked gluten slow its action, so the amount of gluten it can clear depends on the meal.
Not a treatment and not a licence to eat gluten. Keep a strict gluten-free diet. Trials did not show protection of the intestine, and it can at most be considered as an extra layer against accidental exposure, after discussion with your gastroenterologist.
Not studied. Do not rely on it to prevent an allergic reaction to wheat.
It reduces gluten in the stomach, but no trial shows that it reduces symptoms.
Not studied. Ask a clinician or pharmacist before use, and check the product's other ingredients.
Not studied in children.
Tip: Do not take it after an allergic reaction to an enzyme supplement. With a mould allergy alone, check with your clinician before use
AN-PEP has an evidence score of 3.5/10 — emerging evidence based on 11 indexed studies. An oral enzyme from the mould Aspergillus niger that breaks down gluten in the stomach. Small trials show it lowers the gluten reaching the small intestine after a meal, but it is not a treatment for coeliac disease. It does not make gluten safe in coeliac disease or wheat allergy, and it must not replace a gluten-free diet. Representative study: PMID 38617446.
Dosing for AN-PEP: Taken at the start of a meal that may contain gluten, per meal rather than as a daily dose. Study example only: the longest trial gave two 325 mg capsules (about 70% enzyme preparation) with each of three meals a day for 4 weeks. Capsule weight is not the active-enzyme dose: products label strength in activity units that are not comparable across brands, and no trial defines how much enzyme clears a given amount of gluten. AN-PEP does not make gluten safe in coeliac disease or wheat allergy, and it must not replace a gluten-free diet. Individual needs vary, so check the right dose for you with a healthcare provider.
The best time to take AN-PEP is with meals. Take it with food. The enzyme acts on gluten in the stomach, so it has to be there at the same time as the food.
AN-PEP has a safety rating of "moderate". That is a category, not a measure of individual risk, and there are precautions worth knowing. Reported side effects include allergic reaction in people sensitised to the enzyme. How often they occur is not established for all of them. Use caution if any of these apply to you: Using it in order to eat gluten with coeliac disease: it is not a treatment for coeliac disease and does not make gluten safe; Previous allergic reaction to AN-PEP or another enzyme supplement, unless an allergist has confirmed this product does not contain the enzyme you reacted to; Mould allergy: the product is made using the mould Aspergillus niger, so check with your clinician before use.
Lactase
Too few graded studiesA digestive enzyme taken with dairy to break down lactose. Small placebo-controlled challenge trials mostly show less breath hydrogen and, in most, fewer symptoms in people with lactose malabsorption, but responses vary widely between people and products and no pooled analysis in adults exists.
Digestive Enzymes
Too few graded studiesEnzyme blend that helps break down proteins, fats and carbohydrates. Small trials suggest less discomfort in functional dyspepsia, but the evidence for everyday bloating is mixed.
Oral Proteolytic Enzymes
Too few graded studiesCombinations of protein-cleaving enzymes (trypsin, chymotrypsin, papain, bromelain), often with rutoside, taken between meals for joint pain and swelling. In osteoarthritis they were non-inferior to diclofenac in two 6-week trials designed to test that, and a pooled reanalysis reported fewer adverse events than diclofenac, but placebo-controlled evidence is mixed and a 721-person ankle sprain trial found no benefit.
Diamine Oxidase (DAO)
Too few graded studiesAn oral enzyme, usually from pig kidney or pea sprouts, taken just before meals to break down histamine from food in the gut. Small trials in people with suspected histamine intolerance report fewer symptoms, but the trials in migraine, urticaria, fibromyalgia and insomnia mostly failed to show a clear difference from placebo.
Edited by Dr. Baher Al Hakim · Last updated October 2026 · evidence from 11 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.